ASPPH logo

Connect

Partner News

Partner News

DHHS Funding Opportunities

FUNDING OPPORTUNITIES from the Department of Health and Human Services (DHHS)

________________________________________________________

Department of Health and Human Services – Centers for Disease Control and Prevention – ERA – US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children

Proposal Due Date: February 8, 2021

Expected Number of Awards: 7

Estimated Total Program Funding: $68,250,000

Award Ceiling: $1,950,000

Award Floor: $1,600,000

Funding Opportunity Number: RFA-IP-21-002

Purpose: The goal of this Notice of Funding Opportunity (NOFO) is to support a network of US institutions to develop and implement standard research protocols to conduct prospective active surveillance for: a) acute gastroenteritis (AGE) due to norovirus, rotavirus and other enteric viruses; b) acute respiratory illnesses (ARI) due to respiratory viruses including, but not limited to, influenza, RSV, parainfluenza viruses, human metapneumovirus, rhinoviruses, enteroviruses (including EV-D68), adenoviruses, and coronaviruses (including SARS-CoV-2); and c) acute flaccid myelitis (AFM) syndrome and multisystem inflammatory syndrome in children (MIS-C) among pediatric patients seeking healthcare at medical institutions. The network should also provide accurate estimates of the effectiveness in this population of influenza, rotavirus, COVID-19 and other vaccines against respiratory or enteric virus-associated illnesses projected to become available during the period of performance (e.g., RSV, norovirus). Participating institutions should identify AGE, ARI, AFM and MIS-C illnesses among pediatric patients seeking healthcare or diagnostic testing for acute illness in inpatient, outpatient and emergency departments. Recipients should enroll patients meeting standard symptom criteria, and confirm viral infection using approved molecular assays. Vaccine effectiveness (VE) estimates will be calculated. Estimates of VE, burden of disease, and information on the natural history of disease will be used to: a) inform best practices for diagnosis and treatment protocols; b) inform vaccine recommendations; and c) assess public health impact of vaccination and public health programs to prevent viral illness-related healthcare encounters and medical visits among pediatric populations.

View more details on this opportunity.

 

Department of Health and Human Services – Health Resources and Services Administration – Nursing Workforce Diversity (NWD) Program

Proposal Due Date: January 19, 2021

Expected Number of Awards: 32

Estimated Total Program Funding: $16,100,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: HRSA-21-020

Purpose: The purpose of the NWD program is to increase nursing education opportunities for individuals who are from disadvantaged backgrounds (including racial and ethnic minorities underrepresented among registered nurses).

View more details on this opportunity.

 

Department of Health and Human Services – Health Resources and Services Administration – Rapid Response Rural Data Analysis and Issue Specific Rural Research Studies

Proposal Due Date: January 29, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $500,000

Award Ceiling: $500,000

Award Floor:

Funding Opportunity Number: HRSA-21-029

Purpose: This notice announces the opportunity to apply for funding under the Rapid Response Rural Data Analysis and Issue Specific Rural Research Studies Program. The purpose of this program is to assist rural communities with conducting rapid data analyses and short term issue-specific rural research studies to understand the impact of current and proposed policies and regulations as well as provide information that will improve health care in rural America.

Due to the nature of rural policy analysis and formulation, rural organizations and health care providers often require timely information that is available only through specialized analysis of databases of information compiled by the Centers for Medicare and Medicaid Services (CMS), other federal and state agencies, or private organizations. The recipient is responsible for collaborating with agencies in the Department of Health and Human Services (HHS) to compile and analyze data that is requested in a timely manner. The recipient will also collaborate with rural stakeholders to determine what data sets are needed. These collaborative efforts are vital because most rural groups and individuals do not have the capacity to store the data sets, the staff expertise to refine and analyze the data, nor the technology necessary to run statistical analyses.

View more details on this opportunity.

 

Department of Health and Human Services – Health Resources and Services Administration – Leadership Education in Neurodevelopmental and Other Related Disabilities (LEND)

Proposal Due Date: February 16, 2021

Expected Number of Awards: 55

Estimated Total Program Funding: $32,245,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: HRSA-21-041

Purpose: This notice solicits applications for the Leadership Education in Neurodevelopmental and Other Related Disabilities (LEND) training program, and the option of a single, 1-year LEND supplement when funds are available, to expand or develop programs able to diagnose or rule out individuals with autism spectrum disorder (ASD) or other developmental disabilities (DD) across their lifespan.

The purpose of the LEND program is to improve the health of individuals who have, or are at risk for developing, ASD/DD by providing graduate-level training in maternal and child health interdisciplinary leadership education in neurodevelopmental and related disabilities programs.

View more details on this opportunity.

 

Department of Health and Human Services – Health Resources and Services Administration – Building Capacity to Improve Collecting and Reporting Viral Suppression Data to the Medicaid Adult Core Set

Proposal Due Date: February 16, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $4,000,000

Award Ceiling: $4,000,000

Award Floor:

Funding Opportunity Number: HRSA-21-083 

Purpose: This notice announces the opportunity to apply for funding under the Building Capacity to Improve Collecting and Reporting Viral Suppression Data to the Medicaid Adult Core Set cooperative agreement, as a Special Project of National Significance. This initiative seeks to develop strategies to build capacity among HIV surveillance and Medicaid programs for reporting high-quality HIV viral suppression data to comply with reporting of the HIV Viral Load Suppression (HVL-AD) measure on the Medicaid Adult Core Set. The Centers for Medicare and Medicaid Services (CMS) Child and Adult Core Set Annual Review Workgroup has encouraged efforts to create partnerships among federal agencies (CMS, Centers for Disease and Control and Prevention (CDC), and HRSA); Medicaid and public health agencies; and managed care plans to help states gain access to the laboratory data required to measure viral suppression. Recommendations from the workgroup include the sharing of information and lessons learned across states as necessary. This initiative seeks to support the implementation of the recommendations from the HIV/AIDS Health Improvement Affinity Group (HHIAG) with the ultimate goals of improving health outcomes for people with HIV through more efficient and complete strategies in the reporting of viral suppression measures.

View more details on this opportunity.

 

Department of Health and Human Services – Health Resources and Services Administration – Advanced Nursing Education – Sexual Assault Nurse Examiners (ANE-SANE) Program

Proposal Due Date: February 17, 2021

Expected Number of Awards: 16

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: HRSA-21-016

Purpose: The purpose of the ANE-SANE program is to fund advanced nursing education to train and certify Registered Nurses (RNs), Advanced Practice Registered Nurses (APRNs), and Forensic Nurses (FNs) to practice as sexual assault nurse examiners (SANEs). The program aims to increase the supply and distribution of qualified working SANEs and expand access to sexual assault forensic examinations. By expanding access to SANEs, the ANE-SANE program aims to provide better physical and mental health care for survivors of sexual assault and domestic violence leading to better evidence collection and potentially higher prosecution rates.

View more details on this opportunity.

 

Department of Health and Human Services – Health Resources and Services Administration – National Maternal and Child Health Consortium for Oral Health Systems Integration and Improvement

Proposal Due Date: February 17, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $1,325,000

Award Ceiling: $1,325,000

Award Floor:

Funding Opportunity Number: HRSA-21-037

Purpose: This notice announces the opportunity to apply for funding under the National Maternal and Child Health Consortium for Oral Health Systems Integration and Improvement, hereafter referred to as the Consortium. The Maternal and Child Health Bureau (MCHB) will award one cooperative agreement recipient to lead a group of nationally recognized expert organizations in oral health care.

The purpose of the Consortium is to develop and expand accessible, high-quality integrated preventive oral health care for maternal and child health (MCH) populations by providing targeted technical assistance (TA)1 to MCHB oral health Special Projects of Regional and National Significance (SPRANS) and Title V MCH Services Block Grant Program (Title V) award recipients, utilizing a learning collaborative (LC) approach. The Consortium’s lead, in collaboration with Consortium partners and key national stakeholders, will advance excellence in oral health care TA in support of preventive oral health care delivery, with an emphasis on MCH safety net services.2 To achieve its purpose, the Consortium will perform three core functions:

1) Identify Gaps and Barriers – Encompass key elements of the MCH Pyramid of Services3 to identify and address gaps and barriers within systems of care that prevent optimal delivery of preventive oral health care that serve MCH populations.

2) Improve MCH Systems of Care4 – Foster improvements within MCH systems of care that overcome identified gaps and barriers to optimize delivery of preventive oral health care and reduce oral health disparities among MCH populations by better integrating oral health and primary care.

3) Translate Evidence into Practice – Raise awareness and knowledge through the dissemination of new and reliable resources and guidance that serve to reduce the oral health disparities among MCH populations.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)

Proposal Due Date: Submission dates vary by awarding IC.  See Table of IC-Specific Information, Requirements and Staff Contacts for more details.

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PA-21-071

Purpose: The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed in the link) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project.  Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Strengthening HIV Prevention Efforts for Women in the Southern U.S. (R34 Clinical Trial Optional)

Letter of Intent Due Date: December 11, 2020

Proposal Due Date: January 11, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-MH-21-150

Purpose: The goal of this concept is to encourage new strategies that incorporate multiple levels of influence to reach women in the southern U.S. with targeted HIV prevention strategies. The initiative aims to: (1) elucidate barriers and facilitators to the utilization of HIV prevention strategies among southern U.S.-based women; and (2) develop and test novel interventions to enhance the uptake and adherence to HIV prevention strategies among women living in the southern U.S.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Strengthening HIV Prevention Efforts for Women in the Southern U.S. (R01 Clinical Trial Optional)

Letter of Intent Due Date: December 11, 2020

Proposal Due Date: January 11, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-MH-21-151

Purpose: The goal of this concept is to encourage new strategies that incorporate multiple levels of influence to reach women in the southern U.S. with targeted HIV prevention strategies. The initiative aims to: (1) elucidate barriers and facilitators to the utilization of HIV prevention strategies among southern U.S.-based women; and (2) develop and test novel interventions to enhance the uptake and adherence to HIV prevention strategies among women living in the southern U.S.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Biological Testing Facility (X01 Clinical Trial Not Allowed)

Proposal Due Date: January 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-078

Purpose: The purpose of this FOA is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program. This FOA aims to position innovative and validated methods for future clinical development. Applicants do not need to have current NIH funding to apply, but priority may be given to programs receiving NIH support at the time of application submission.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)

Proposal Due Date: January 25, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-041

Purpose: The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions.

The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chair’s Grant, the Coordinating Center, and Resource Centers, when appropriate.

Specifically, this FOA encourages applications for the Chair’s grant, which includes the scientific rationale, study aims and significance of the research project.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)

Proposal Due Date: January 25, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-042

Purpose: The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions.  The NEI UG1-supported studies are typically funded as a group of linked companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. For less organizationally complex projects, details pertaining to data management and statistical analyses, resource center and recruitment activity may be included as part of the Chair’s Grant application. Specifically, this FOA encourages applications for the Coordinating Center grant, which provides details of the Coordinating Center’s responsibilities and operations.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required)

Proposal Due Date: January 25, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-043

Purpose: The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions.   The NEI UG1-supported studies are typically funded as a group of linked companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate.  For less organizationally complex projects, details pertaining to data management and statistical analyses, resource center and recruitment activity may be included as part of the Chair’s Grant application. Specifically, this FOA encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high risk clinical trial.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Cancer Research Education Grants Program – Research Experiences (R25 Clinical Trial Not Allowed)

Proposal Due Date: January 25, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-067

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Cancer Research Education Grants Program – Courses for Skills Development (R25 Clinical Trial Not Allowed)

Proposal Due Date: January 25, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-066

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on     Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Cancer Research Education Grants Program – Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

Proposal Due Date: January 25, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-065

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on     Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)

Letter of Intent Due Date: January 9, 2021

Proposal Due Date: February 9, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-MH-21-105

Purpose: The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)

Letter of Intent Due Date: January 9, 2021

Proposal Due Date: February 9, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-MH-21-106

Purpose: The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 22, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-CA-21-005

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 22, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-CA-21-006

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 22, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-CA-21-004

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 22, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-059

Purpose: The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 22, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-058

Purpose: The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 22, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-057

Purpose: The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 22, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-056

Purpose: The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Outstanding New Environmental Scientist (ONES) Award (R01 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 26, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-ES-21-001

Purpose: The Outstanding New Environmental Scientist (ONES) Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on the understanding the effects of environmental exposure on peoples health.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Initiative for Maximizing Student Development (IMSD) (T32 – Clinical Trial Not Allowed)

Proposal Due Date: February 26, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-025

Purpose: The goal of the Initiative for Maximizing Student Development (IMSD) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-intensive institutions (i.e., those with NIH Research Project Grant funding averaging greater than or equal to $7.5 million in total costs (direct and F&A/indirect) per year over the last three fiscal years).

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32 – Clinical Trial Not Allowed)

Proposal Due Date: February 26, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-026

Purpose: The goal of the Graduate Research Training Initiative for Student Enhancement (G-RISE) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-active institutions (i.e., those with NIH Research Project Grant funding averaging less than $7.5 million in total costs (direct and F&A/indirect) per year over the last three fiscal years).

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)

Proposal Due Date: March 5, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-081

Purpose: The purpose of this initiative is to support research to design and implement effective interventions to enhance health advantages and reduce health disparities among US immigrant populations.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01 Clinical trial not allowed)

Proposal Due Date: March 5, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-080

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Small Vessel VCID Biomarker Validation Consortium Sites (U01) (Clinical Trials Not Allowed)

Letter of Intent Due Date: February 09, 2021

Proposal Due Date: March 9, 2021

Expected Number of Awards: 7

Estimated Total Program Funding: $8,400,000

Award Ceiling: $800,000

Award Floor:

Funding Opportunity Number: RFA-NS-21-005

Purpose: The purpose of this funding opportunity announcement is to invite applications to an open competition to be one of up to 7 supported sites in the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium, established under RFA-NS-16-019 and RFA-NS-16-020, pursued initial stages of multi-site validation of 11 candidate imaging-based and fluid-based biomarkers. The primary objective of the next 5 years is to carry out comprehensive multi-site clinical validation of up to six of these 11 biomarkers to be selected by the NINDS in a process separate from this FOA. The focus will be validation in longitudinal studies of diverse all-comers populations that are typical in clinical settings in the United States. The network of sites will provide scientific expertise and experimental infrastructure to pursue these goals synergistically including with the Coordinating Center (RFA-NS-21-004). At the conclusion of clinical validation each biomarker will have a designated category and context of use as defined by the FDA and a finalized public protocol that describes all details needed to utilize the biomarker. The sites will drive the consortium scientifically and contribute administratively to comprehensive rigorous clinical validation of biomarkers for future clinical trials, including in large phase III trials, and for generating scientific breakthroughs in our understanding and treatment of VCID.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed)

Letter of Intent Due Date: February 09, 2021

Proposal Due Date: March 9, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $2,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-NS-21-004

Purpose: The purpose of this funding opportunity announcement (FOA) is to have an open competition to support a Coordinating Center for the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium was established under RFA-NS-16-019 and RFA-NS-16-020. The goal of the next phase, under RFA-NS-20-004 (Coordinating Center) and RFA-NS-20-005 (sites), is to complete clinical validation of biomarkers initially developed during the first 5-year funding cycle of this program. The Coordinating Center will consist of: (i) an Administrative Core responsible for organizing, coordinating and administratively driving Consortium activities; and (ii) a Data Core that will coordinate, receive, collect, and share data, including de-identified clinical data. The Coordinating Center will drive the consortium administratively and contribute scientifically to validation of biomarkers with specified context of use for future clinical trials, including in large phase III trials, with general and diverse populations, and for generating scientific breakthroughs in our understanding and treatment of VCID.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Contraceptive Development Research Centers Program (P50 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: March 30, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-HD-22-003

Purpose: The primary purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Research Development Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success. Additionally, it allows for behavioral/social science, including market research to test user acceptability, research projects that are responding and well-coordinated to the contraceptive product being developed.  The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

Proposal Due Date: May 7, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-069

Purpose: This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Studies that move the science of HIV and aging into new directions with little or no preliminary data are appropriate for this activity code. Applications appropriate for this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-20-018.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

Proposal Due Date: May 7, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-068

Purpose: This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-20-018.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Diabetes Research Centers (P30 Clinical Trial Optional)

Letter of Intent Due Date: April 20, 2021

Proposal Due Date: May 20, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-DK-20-025

Purpose: This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases.  Diabetes Research Centers support two primary research-related activities:  Research Core services and a Pilot and Feasibility (P and F) program.  All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas.  The NIDDK Diabetes Research Centers program in 2020 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research.  General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: July 19, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-023

Purpose: As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: July 19, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-022

Purpose: As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

Proposal Due Date: See Link

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-079

Purpose: This Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI’s mission. The NHLBI expects that applications to this FOA will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

View more details on this opportunity.

 

Department of Health and Human Services – National Institutes of Health – Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: September 28, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-CA-21-004

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

View more details on this opportunity.